Mymd Pharmaceuticals (NASDAQ:QCLS) Cut to “Sell” at Wall Street Zen

Wall Street Zen lowered shares of Mymd Pharmaceuticals (NASDAQ:QCLS) from a hold rating to a sell rating in a research note published on Saturday.

Separately, Weiss Ratings began coverage on shares of Mymd Pharmaceuticals in a research note on Wednesday, May 13th. They set a “sell (e+)” rating on the stock. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Mymd Pharmaceuticals currently has a consensus rating of “Sell”.

Mymd Pharmaceuticals Trading Down 3.4%

QCLS stock opened at $2.82 on Friday. Mymd Pharmaceuticals has a 1-year low of $2.50 and a 1-year high of $12.24. The company’s fifty day simple moving average is $3.52. The company has a market capitalization of $11.76 million, a price-to-earnings ratio of -0.14 and a beta of 2.16.

Mymd Pharmaceuticals (NASDAQ:QCLS) last issued its earnings results on Friday, May 15th. The company reported ($0.19) earnings per share for the quarter.

Mymd Pharmaceuticals Company Profile

MyMD Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for immune-related and other serious diseases. The company has worked on product candidates designed to address conditions involving inflammation, immune system dysfunction, and age-related disease processes.

The company’s pipeline has included drug development programs in areas such as autoimmune and inflammatory disorders, with an emphasis on advancing compounds through preclinical and clinical evaluation.